Organisation paid for research Program year 2025 Source: CMS Open Payments

Acuro Research Inc

Neither a doctor nor a teaching hospital

Research payments

$46,333

14 payments

Through program year 2025, Acuro Research Inc is reported as receiving $46,333 in research payments, across 14 payments.

By program year

2 rows

Year	Kind	Amount	Payments
2025	Research	$38,615	10
2024	Research	$7,717	4

Breakdown

Who paid Research payments · program years 2024–2025

Novartis Pharmaceuticals Corporation $30,918 6 payments
Teva Pharmaceuticals USA, Inc. $10,380 2 payments
CSL Behring $2,829 4 payments
Pfizer Inc. $2,206 2 payments

Studies the money was for Research payments · program years 2024–2025

A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista $23,201 2 payments
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma $10,200 1 payment
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1-antihistamines $5,349 1 payment
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema $2,829 4 payments
A Phase 2B Randomized Doubleblind 12Week Placebocontrolled Study With A 12Week Doubleblind Extension Period to Evaluate the Efficacy Safety and Tolerability of Ritlecitinib Pf06651600 in Adult Participants With Chronic Spontaneous Urticaria $2,206 2 payments
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Chronic Spontaneous Urticaria Patients Who Completed the Preceding Remibrutinib Phase 3 Studies $1,965 1 payment
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Remibrutinib (Lou064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (Csu) Patients Inadequately Controlled By H1-Antihistamines $370 1 payment
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma $180 1 payment
A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of Ligelizumab (Qge031) in the Treatment of Chronic Inducible Urticaria (Cindu) in Adolescents and Adults Inadequately Controlled By H1-Antihistamines $33 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.